NBC News' Tom Brokaw was diagnosed with multiple myeloma last year, NBC News reported.
Brokaw, who is 74, is a special correspondent at the network. He was diagnosed with the cancer, which affects the plasma cells in the bone marrow, last August at the Mayo Clinic.
"With the exceptional support of my family, medical team and friends, I am very optimistic about the future and look forward to continuing my life, my work and adventures still to come," he said in a statement posted on the NBC News website.
Even though there is no cure for multiple myeloma, the condition is considered treatable, USA Today reported. Survival time has increased significantly: For instance, 20 years ago, people with the cancer only survived two or three years after being diagnosed. Now, they survive five to seven years after being diagnosed, and sometimes even more than a decade.
According to the American Cancer Society, there are expected to be 24,050 new cases and 11,090 deaths from multiple myeloma in the U.S. this year. A person's lifetime risk of developing the condition is one in 149.
Multiple myeloma occurs when abnormal plasma cells in the bone marrow multiply, eventually collecting in the bone marrow and bone. Since plasma cells are responsible for making proteins called antibodies, which are the body's way of fighting infection, that means an increase in the blood levels of abnormal proteins, according to the Mayo Clinic.
As a comparison: In healthy people, plasma cells make up 5 percent of the cells in bone marrow. But in people with multiple myeloma, plasma cells could make up more than 10 percent of the cells in bone marrow, the Mayo Clinic explained. When there are too many plasma cells, it eventually affects the body's immune system.
While the condition may not cause symptoms in its early stages, it can lead to kidney failure, bone damage, fatigue due to anemia, and high blood calcium levels (which manifests as nausea, confusion, constipation and excessive thirst).
If there are not any symptoms from multiple myeloma, doctors may decide treatment is not yet needed, the National Institutes of Health pointed out. However, if symptomatic, the condition may require chemotherapy, radiation therapy, targeted therapy or stem cell transplantation.
Support HuffPost
Our 2024 Coverage Needs You
Your Loyalty Means The World To Us
At HuffPost, we believe that everyone needs high-quality journalism, but we understand that not everyone can afford to pay for expensive news subscriptions. That is why we are committed to providing deeply reported, carefully fact-checked news that is freely accessible to everyone.
Whether you come to HuffPost for updates on the 2024 presidential race, hard-hitting investigations into critical issues facing our country today, or trending stories that make you laugh, we appreciate you. The truth is, news costs money to produce, and we are proud that we have never put our stories behind an expensive paywall.
Would you join us to help keep our stories free for all? Your contribution of as little as $2 will go a long way.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. Would you consider becoming a regular HuffPost contributor?
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. If circumstances have changed since you last contributed, we hope you’ll consider contributing to HuffPost once more.
Support HuffPostAlready contributed? Log in to hide these messages.